Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States

INTRODUCTION: Eribulin was approved in the United States (US) in 2010 for patients with metastatic breast cancer (MBC) who previously received at least two chemotherapeutic regimens, including anthracycline and taxane in the adjuvant or metastatic setting. With significant changes to the treatment l...

Descripción completa

Detalles Bibliográficos
Autores principales: Mougalian, Sarah S., Kish, Jonathan K., Zhang, Jingchuan, Liassou, Djibril, Feinberg, Bruce A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107067/
https://www.ncbi.nlm.nih.gov/pubmed/33491157
http://dx.doi.org/10.1007/s12325-020-01613-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107067/
https://www.ncbi.nlm.nih.gov/pubmed/33491157
http://dx.doi.org/10.1007/s12325-020-01613-6

Ejemplares similares